SND 462 AMH
Alternative Names: SND-462-AMHLatest Information Update: 05 Feb 2025
At a glance
- Originator Floratek Pharma
- Class Antineoplastics; Flavonoids; Polyphenols; Small molecules
- Mechanism of Action RIOK2 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Lymphoma
Most Recent Events
- 19 Dec 2024 Preclinical trials in Colorectal cancer in Switzerland (unspecified route) before December 2024 (Floratek Pharma pipeline, December 2024)
- 19 Dec 2024 Preclinical trials in Lymphoma in Switzerland (unspecified route) before December 2024 (Floratek Pharma pipeline, December 2024)
- 22 Mar 2024 Pharmacodynamics data for the preclinical studies in Lymphoma presented at the American Association for Cancer Research (AACR-2024)